TrimRx's Blog
Retatrutide Switching to or From: Transition Protocols & Dose Conversion
Retatrutide isn’t FDA approved yet. The TRIUMPH Phase 3 program is targeting late 2025 submission with potential approval in 2026 or 2027.
Retatrutide Storage, Travel & Handling: Everything You Need to Know
Introduction Retatrutide stability data published by Eli Lilly in Phase 2 supports the standard GLP-1-class storage profile: refrigerated long-term, room temperature for limited periods,…
Retatrutide Side Effects: Complete Profile, Management & When to Call Your Doctor
Retatrutide’s side effect profile in Phase 2 trials looked similar to tirzepatide.
Retatrutide Real Results: Weight Loss Timeline & What Patients Report
Retatrutide’s Phase 2 trial produced the largest mean weight loss ever recorded in a GLP-1-class obesity study.
Retatrutide How It Works: Mechanism of Action Explained
Retatrutide is the first triple receptor agonist to reach late-stage human trials for obesity.
Retatrutide Latest Research: New Indications, Trials & What’s Coming
Retatrutide is the most-watched investigational obesity drug of 2026.
Retatrutide Who Should (and Shouldn’t) Take It: Eligibility & Contraindications
Retatrutide is still in Phase 3 testing. Eli Lilly’s TRIUMPH program ran enrollment through 2024 with topline data expected in 2026.
Retatrutide Drug Interactions: What You Can and Can’t Take with It
Retatrutide isn’t on the market yet, so there’s no FDA-issued interaction label.
Retatrutide Dosing Guide: Schedule, Titration & What to Expect Each Week
Retatrutide is dosed once weekly by subcutaneous injection.
